Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U2 small nuclear 35, pseudogene (RNU2-35P) is a genomic DNA sequence classified as a pseudogene of the U2 small nuclear RNA (snRNA) gene, specifically annotated as the 35th member in this pseudogene family. U2 snRNA genes encode RNA molecules that are core components of the spliceosome and essential for pre-mRNA splicing, but pseudogenes like RNU2-35P do not produce functional RNA transcripts and are not involved in biological processes or disease pathways. There is no evidence to suggest that RNU2-35P has any regulatory or pathological relevance in humans[1]. Notes: - RNU2-35P is frequently catalogued in genomic databases as a pseudogene and not an active gene, enzyme, receptor, or recognized therapeutic target[1]. - While functional U2 snRNA is crucial for mRNA splicing[2][3][4], RNU2-35P does not contribute to this process. - No known drugs or compounds interact with RNU2-35P, nor is it used as a biomarker or target for therapy. Summary: RNU2-35P represents a pseudogene of U2 snRNA, is not a therapeutic target or a functional gene, and has no current implication in biology or medicine[1].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 35, pseudogene (RNU2-35P).